ClinicalTrials.gg
RecruitingNCT04619862Updated May 8, 2024

Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)

A Phase 2 interventional study of Gabapentin and Placebo in Pain, Neuropathic Pain and Irritability, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Primary conditionNeuralgiaRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neuralgia
Why
  1. The study's listed conditions name Neuralgia, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing gabapentin in Neuralgia — 2 open to participants now, 2 under way, none of them phase 3. Gabapentin · Neuralgia.

Planned enrollment
14th of 17
5 · median 29
Started
2021
with 1 other
Phase 2
5 of 17
1 open now
Registered
13th of 17
by date

Among the 17 studies testing gabapentin in Neuralgia, this one is the 14th largest by planned enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 13th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

2 of the 17 studies testing gabapentin in Neuralgia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing gabapentin in Neuralgia, or all of them as a file.
02

Study summary

Children born with severe brain-based developmental disabilities frequently experience persistent unexplained periods of pain and irritability, often compounded by a limited capacity to communicate their distress. The investigators call this entity Pain and Irritability of Unknown Origin (PIUO). The rationale of this trial is to identify the clinical effect size of gabapentin in reducing and resolving pain in children with developmental brain disorders, specifically those with severe neurological impairment (SNI).

Read the detailed description

Background

Children with SNI may experience nociceptive-inflammatory pain as a result of their specific medical condition or procedures. Often, however, it is not clear what underlies the pain behavior as there is no clear inciting noxious event. The investigators define this entity of pain without an obvious source as Pain and Irritability of Unknown Origin (PIUO).

The investigators' work to date has developed an efficient, focused clinical pathway to evaluate children with SNI for all potential sources of nociceptive-inflammatory pain. Using this approach the "unknown" element of pain in these children is reduced and a source of PIUO may be found in individual cases, increasing the potential for treatment. Nevertheless there are children, who at the end of a thorough evaluation guided by a clinical pathway, will still have PIUO. These children may benefit from adjuvant analgesics such as gabapentin.

The evidence base supporting the use of gabapentin for pain and irritability in infants and children with neurological impairment rests on case series publications describing a limited number of retrospective cases. The lack of prospective, randomized studies, even for this commonly used medication, underpins the rationale for this trial.

Objectives

The primary objective of the pilot trial is to evaluate the clinically significant difference of gabapentin to decrease pain and irritability in children with SNI, when the source of pain and irritability is attributed to neurological dysregulation (nociplastic pain), as measured by parent-reported pain scores.

The investigators will compare the gabapentin versus placebo along an escalating dose range for both individual subjects and for the group. The investigators will aggregate the results of the completed N-of-1 trials across all subjects to estimate the group level comparative effectiveness of gabapentin in reducing pain and irritability.

Outcomes from this study will help with designing larger randomized control trials, especially with sample size and power calculations. It will also provide prospective information on drug effect.

Trial Design

This trial uses a single randomized multiple-measures cross-over design (N-of-1), with results aggregated over several subjects. This design is well-suited to outcomes that are highly specific to each individual and not amenable to precise measurement across a large cohort. The heterogenous nature of pain and irritability responses in children are more likely to be personally specific and characteristic, rather than generalizable.

Subjects will switch between gabapentin (G) and placebo (P) in a randomized order. The sequence of whether G precedes P (GP) or P precedes G (PG) will be randomized by the study pharmacist, and neither the clinician nor the subject (parent/caregiver) will know the sequence. Each subject will serve as their own control and experiment, allowing for a finer assessment of the treatment efficacy within each patient.

The primary variable assessed is the child's pain score. Pain and irritability will be measured using the Non-Communicating Children's Pain Checklist - Revised (NCCPC-R) at specified intervals throughout the randomized sequence of G : P. Additional measures of parent/caregiver burden and impact on their daily function will be undertaken weekly with the PROMIS-57, a tool adapted to measure the impact of the child's pain and irritability on parental functioning. Other measures will be of usual, known side effects (e.g., sedation) and of any unexpected adverse events.

03

Conditions studied

  • Pain
  • Neuropathic Pain
  • Irritability

Browse trials for

04

In context

Neuralgia Reclassified

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

This study's planned enrollment of 5 is below the median of 52 across 833 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 months to 18 years with SNI (from any cause) with unexplained pain and irritability and whose cognitive or communication impairments prevent determination of pain location, cause, and type will be eligible to participate.
  • Eligible children will have cognitive impairment or be non-verbal and have severe levels of disability equivalent to Gross Motor Functional Classification System (GMFCS) scores of 3, 4 or 5 as well as Communication Function Classification System (CFCS) level 4 or 5.
  • Eligible children will score >3 on two scales administered via an Eligibility Screening that measures persistence and distress level the child is experiencing as well as identifies the type of pain and irritability as PIUO - with no obvious cause or explanation. The score of >3 on the scale measuring pain persistence and distress level confirms that the child is experiencing pain and irritability more than "a little" on "some days".
  • The will be evidence of a comprehensive evaluation of PIUO in the child's medical history, showing no evidence for treatable sources (nociceptive-inflammatory) of pain and/or irritability symptoms.

Exclusion criteria

Exclusion Criteria:

  • Children not within the specified age range
  • Children with communication capabilities and cognitive development to localize their pain.
  • Participants whose pain and or irritability is diagnosed through completion of the PIUO Pathway during the enrollment phase of the trial.
  • Patients with a known /allergy to the study medication
  • Patients who are actively participating in another experimental therapy study for pain and/or irritability.
  • Patients who are a poor medical risk because of other systemic diseases or active uncontrolled infections.
  • Patients who score A or B on the Pain Survey
  • Patients who have an active source of nociceptive-inflammatory pain at the time of enrolment (e.g., post-operative pain)
  • Patients with active renal disease, known renal impairment or \< 60 mL/min/1.73 m2 (if known).
  • Patients with known significant hepatic impairment at the discretion of the investigator.
  • Patients with abnormal (if available) at the discretion of the investigator.
  • Patients with diagnosis of sickle cell disease.
  • Parents who do not speak one of Canada's two official languages (English or French)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Medication

    Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower. The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: \< 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day.

    Drug: Gabapentin

  • Placebo comparator
    Placebo

    Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.

    Drug: Placebo

Interventions

  • See arm descriptions

  • DrugPlacebo

    See arm descriptions

07

What researchers measure

Primary outcomes

  1. Mean pain and irritability score

    The mean pain and irritability score on the Non-Communicating Children's Pain Checklist Revised (NCCPC-R) on active drug compared to placebo.

    Time frame: Days 11-19

Secondary outcomes

  1. Identification of lowest effective dose

    For patients who benefited from gabapentin, identification of the lowest dose that was effective in reducing pain scores, as shown by a lower Non-Communication Children's Pain Checklist - Revised (NCCPC-R) score compared to baseline.

    Time frame: Days 11-19 on active drug

  2. Maximal effect dosage

    For patients who benefited from gabapentin, identification of the maximal effect dosage as measured by the largest improvement in the Non-Communicating Children's Pain Checklist - Revised (NCCPC-R) score compared to baseline.

    Time frame: Days 11-19 on active drug

  3. Identification of latency time

    Identification of the latency time in days to the onset of maximum relief of pain and irritability as measured by the Non-Communication Children's Pain Checklist - Revised (NCCPC-R) score

    Time frame: Days 0-19

  4. Adverse Events collection

    Adverse Events collection demonstrates the AEs on treatment arm do not exceed the frequency found in the Product Monograph for children receiving gabapentin

    Time frame: Through Sequence 1 and 2, total of 55 days

Other outcomes

  1. Improvement in parent fatigue levels

    Patient Reported Outcome Measures Information System - 57 (PROMIS-57) scores on the medication arm compared to the placebo arm

    Time frame: Day 1 of Sequence 1 and 2 (each Sequence is 26 days with a 3 day washout period in between) and Study End, day 55

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Mar 2026, 58 months after the start.

Of 58 phase 2 interventional studies under Neuralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Nov 6, 2020
StartActual
May 15, 2021
Primary completionEst.
Mar 31, 2026
CompletionEst.
Apr 30, 2026
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04619862
Collaborators
Canadian Institutes of Health Research (CIHR), Child-Bright Network, BC Children's Hospital Research Institute
Responsible party
Harold Siden (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Nov 6, 2020
Start date
May 15, 2021
Primary completion
Mar 31, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
May 8, 2024

Study contacts

Anne-Mette Hermansen, MA
Contact
ahermansen@bcchr.ca
604 875 2000 ext. 6909
Gail Andrews, RN
Contact
gandrews@cw.bc.ca
604 875 2000 ext. 5345
Hal Siden, MD
principal investigator · BC Children's Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion